{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:16:15Z","timestamp":1787498175920,"version":"build-2736575974"},"reference-count":40,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"6","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: To measure the diagnostic value of T2WI and DWI radiomics model, combined with advanced biomarkers, in distinguishing benign prostatic hyperplasia (BPH), prostate cancer (PCa) and prostatitis. Methods: A total of 90 patients with prostate diseases were selected from our hospital from January 2022 to January 2024. All patients underwent T2WI and DWI MRI examinations. Regions of interest (ROI) were delineated, and imaging features were extracted using radiomics analysis. In addition, novel biomarkers, including Prostate Cancer Antigen 3 (PCA3), Sarcosine, Glypican-1 (GPC1), Urokinase Plasminogen Activator Receptor (uPAR), and Thymidine Kinase 1 (TK1), were analysed for their diagnostic significance. Feature selection was performed using LASSO regression, and a random forest model was established for classification. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic performance of the T2WI and DWI radiomics model with and without biomarker integration. Results: Among the 90 patients with prostate diseases, 50 cases were PCa, 20 cases of prostatitis and 20 cases of BPH were detected by biopsy. The PI-RADS v2 score in the PCa group presented elevation relative to those in the BPH and prostatitis groups (P&lt;0.01). The ADC values in the PCa group were reduced relative to those in the BPH and prostatitis groups (P&lt;0.01). The integration of biomarkers with radiomics analysis led to improved diagnostic performance. The AUC value, sensitivity, and specificity of the T2WI and DWI radiomics model were higher relative to those of PI-RADS V2. Conclusions: The T2WI and DWI radiomics model, when combined with novel biomarkers, enhances the accuracy of distinguishing PCa, BPH, and prostatitis. This approach may provide an advanced diagnostic tool for personalised prostate disease management.<\/jats:p>","DOI":"10.5937\/jomb0-57639","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:07:06Z","timestamp":1751947626000},"page":"1376-1385","source":"Crossref","is-referenced-by-count":1,"title":["Combination of prostate cancer antigen 3 (PCA3), sarcosine, glypican-1 (GPC1), urokinase plasminogen activator receptor (uPAR), and thymidine kinase 1 (TK1), and T2WI and DWI radiomics model for distinguishing benign prostatic hyperplasia, prostate cancer, and prostatitis"],"prefix":"10.5937","volume":"44","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Verze P , Cai T, Lorenzetti S. The role of the prostate in male fertility, health and disease. Nat Rev Urol 2016; 13(7): 379-86.;","DOI":"10.1038\/nrurol.2016.89"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Risbridger GP , Almahbobi GA, Taylor RA. Early prostate development and its association with late-life prostate disease. Cell Tissue Res 2005; 322(1): 173-81.;","DOI":"10.1007\/s00441-005-1121-9"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ratajczak W, Lubkowski M, Lubkowska A. Heat Shock Proteins in Benign Prostatic Hyperplasia and Prostate Cancer. Int J Mol Sci 2022; 23(2).;","DOI":"10.3390\/ijms23020897"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Al-Khalil S, Boothe D, Durdin T, Sunkara S, Watkins P , Yang S, et al. Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review. Int Urol Nephrol 2016; 48(1): 91-7.;","DOI":"10.1007\/s11255-015-1146-2"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Cavada BS, Oliveira MV, Osterne VJS, Pinto-Junior VR, Correia-Neto C, Nascimento KS. Lectins applied to diagnosis and treatment of prostate cancer and benign hyperplasia: A review. Int J Biol Macromol 2021; 190: 543-53.;","DOI":"10.1016\/j.ijbiomac.2021.09.011"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Williams IS, McVey A, Perera S, O'Brien JS, Kostos L, Chen K, et al. Modern paradigms for prostate cancer detection and management. Med J Aust 2022; 217(8): 424-33.;","DOI":"10.5694\/mja2.51722"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Jiao J, Kang F , Zhang J, Quan Z, Wen W, Zhao X, et al. Establishment and prospective validation of an SUV(max) cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by (68)Ga-PSMA PET\/CT: a real-world study. Theranostics 2021; 11(17): 8396-411.;","DOI":"10.7150\/thno.58140"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Kumar V, Jagannathan NR, Thulkar S, Kumar R. Pre-biopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer. Int J Urol 2012; 19(7): 602-13.;","DOI":"10.1111\/j.1442-2042.2012.02995.x"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V. Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multi-parametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. Eur Urol Oncol 2020; 3(5): 615-9.;","DOI":"10.1016\/j.euo.2020.06.007"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hu L, Wei L, Wang S, Fu C, Benker T, Zhao J. Better lesion conspicuity translates into improved prostate cancer detection: comparison of non-parallel-transmission-zoomed-DWI with conventional-DWI. Abdom Radiol (NY) 2021; 46(12): 5659-68.;","DOI":"10.1007\/s00261-021-03268-5"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Liu Y , Wang W, Qin XB, Wang HH, Gao G, Zhang XD, et al. The applied research of simultaneous image acquisition of T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) in the assessment of patients with prostate cancer. Asian J Androl 2019; 21(2): 177-82.;","DOI":"10.4103\/aja.aja_82_18"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Mayerhoefer ME, Materka A, Langs G, H\u00e4ggstr\u00f6m I, Szczypi\u0144ski P , Gibbs P , et al. Introduction to Radiomics. J Nucl Med 2020; 61(4): 488-95.;","DOI":"10.2967\/jnumed.118.222893"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Chen Q, Zhang L, Liu S, You J, Chen L, Jin Z, et al. Radiomics in precision medicine for gastric cancer: opportunities and challenges. Eur Radiol 2022; 32(9): 5852-68.;","DOI":"10.1007\/s00330-022-08704-8"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Li Y, Liu Y, Liang Y, Wei R, Zhang W, Yao W, et al. Radiomics can differentiate high-grade glioma from brain metastasis: a systematic review and meta-analysis. Eur Radiol 2022; 32(11): 8039-51.;","DOI":"10.1007\/s00330-022-08828-x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Conti A, Duggento A, Indovina I, Guerrisi M, Toschi N. Radiomics in breast cancer classification and prediction. Semin Cancer Biol 2021; 72: 238-50.;","DOI":"10.1016\/j.semcancer.2020.04.002"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Shin J, Seo N, Baek SE, Son NH, Lim JS, Kim NK, et al. MRI Radiomics Model Predicts Pathologic Complete Response of Rectal Cancer Following Chemo radio therapy. Radiology 2022; 303(2): 351-8.;","DOI":"10.1148\/radiol.211986"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Scott R, Misser SK, Cioni D, Neri E. PI-RADS v2.1: What has changed and how to report. SA J Radiol 2021; 25(1): 2062.;","DOI":"10.4102\/sajr.v25i1.2062"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Prostate cancer. Nat Rev Dis Primers 2021; 7(1): 8.;","DOI":"10.1038\/s41572-021-00249-2"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m T, Akre O, Aly M, Gr\u00f6nberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis 2018; 21(1): 57-63.;","DOI":"10.1038\/s41391-017-0024-7"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Yacoub JH, Oto A. MR Imaging of Prostate Zonal Anatomy. Radiol Clin North Am 2018; 56(2): 197-209.;","DOI":"10.1016\/j.rcl.2017.10.003"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Zhang KS, Mayer P, Glemser PA, Tavakoli AA, Keymling M, Rotkopf LT , et al. Are T2WI PI-RADS subscores of transition zone prostate lesions biased by DWI information? A multi-reader, single-center study. Eur J Radiol 2023; 167: 111026.;","DOI":"10.1016\/j.ejrad.2023.111026"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Belue MJ, Yilmaz EC, Daryanani A, Turkbey B. Current Status of Biparametric MRI in Prostate Cancer Diagnosis: Literature Analysis. Life (Basel) 2022; 12(6).;","DOI":"10.3390\/life12060804"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Iyama Y, Nakaura T, Katahira K, Iyama A, Nagayama Y, Oda S, et al. Development and validation of a logistic regression model to distinguish transition zone cancers from benign prostatic hyperplasia on multiparametric prostate MRI. Eur Radiol 2017; 27(9): 3600-8.;","DOI":"10.1007\/s00330-017-4775-2"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Head-To-Head Comparison Between Highand Standard-b-Value DWI for Detecting Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol 2018; 210(1): 91-100.;","DOI":"10.2214\/AJR.17.18480"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Jendoubi S, Wagner M, Montagne S, Ezziane M, Mespoulet J, Comperat E, et al. MRI for prostate cancer: can computed high b-value DWI replace native acquisitions? Eur Radiol 2019; 29(10): 5197-204.;","DOI":"10.1007\/s00330-019-06085-z"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Sun H, Du F , Liu Y , Li Q, Liu X, Wang T . DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is 10 ng\/mL. Front Oncol 2022; 12: 925186.;","DOI":"10.3389\/fonc.2022.925186"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Xiaohang L, Bingni Z, Liangping Z, Weijun P , Xiaoqun Y, Yong Z. Differentiation of prostate cancer and stromal hyperplasia in the transition zone with histogram analysis of the apparent diffusion coefficient. Acta Radiol 2017; 58(12): 1528-34.;","DOI":"10.1177\/0284185117698861"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Turkbey B, Purysko AS. PI-RADS: Where Next? Radiology 2023; 307(5): e223128.;","DOI":"10.1148\/radiol.223128"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"O'Shea A, Harisinghani M. PI-RADS: multiparametric MRI in prostate cancer. Magma. 2022; 35(4): 523-32.;","DOI":"10.1007\/s10334-022-01019-1"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Gupta RT, Mehta KA, Turkbey B, Verma S. PI-RADS: Past, present, and future. J Magn Reson Imaging 2020; 52(1): 33-53.;","DOI":"10.1002\/jmri.26896"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Smith CP , T\u00fcrkbey B. PI-RADS v2: Current standing and future outlook. Turk J Urol 2018; 44(3): 189-94.;","DOI":"10.5152\/tud.2018.12144"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, et al. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp 2018; 2(1): 36.;","DOI":"10.1186\/s41747-018-0068-z"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Ferro M, de Cobelli O, Musi G, Del Giudice F , Carrieri G, Busetto GM, et al. Radiomics in prostate cancer: an up-to-date review. Ther Adv Urol 2022; 14: 17562872221109020.;","DOI":"10.1177\/17562872221109020"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Jing G, Xing P, Li Z, Ma X, Lu H, Shao C, et al. Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram. Front Oncol 2022; 12: 918830.;","DOI":"10.3389\/fonc.2022.918830"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Zhang Y, Li W, Zhang Z, Xue Y, Liu YL, Nie K, et al. Differential diagnosis of prostate cancer and benign prostatic hyperplasia based on DCE-MRI using bi-directional CLSTM deep learning and radiomics. Med Biol Eng Comput 2023; 61(3): 757-71.;","DOI":"10.1007\/s11517-022-02759-x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Xu M, Fang M, Zou J, Yang S, Yu D, Zhong L, et al. Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions. Eur J Radiol 2019; 114: 38-44.;","DOI":"10.1016\/j.ejrad.2019.02.032"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Li M, Yang L, Yue Y, Xu J, Huang C, Song B. Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer. Front Oncol 2020; 10: 631831.;","DOI":"10.3389\/fonc.2020.631831"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Shaikh F , Dupont-Roettger D, Dehmeshki J, Awan O, Kubassova O, Bisdas S. The Role of Imaging markers Derived From Advanced Imaging and Radiomics in the Management of Brain Tumors. Frontiers in Oncology 2020; 10.;","DOI":"10.3389\/fonc.2020.559946"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Lee G, Lee HY, Park H, Schiebler ML, van Beek EJ, Ohno Y , et al. Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. European Journal of Radiology 2017; 86: 297-307.;","DOI":"10.1016\/j.ejrad.2016.09.005"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Lo Gullo R, Daimiel I, Morris EA, Pinker K. Combining molecular and imaging metrics in cancer: radiogenomics. Insights Into Imaging 2020; 11(1): 1.;","DOI":"10.1186\/s13244-019-0795-6"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Kombinacija antigena karcinoma prostate 3 (PCA3), sarkozina, glipikana-1 (GPC1), receptora urokinaznog aktivatora plazminogena (uPAR) i timidinske kinaze 1 (TK1) sa radiomiks modelom T2WI i DWI u razlikovanju benigne hiperplazije prostate, karcinoma prostate i prostatitisa"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582506376Y.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:14:16Z","timestamp":1757070856000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582506376Y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-57639","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}